

SUPPLEMENTARY MATERIAL

Table S1. Baseline characteristics of patients with alcohol consumption ($\leq 30/40$ g/d)

Patient characteristics				p ¹	p ²
	Non-OST/ NDU (N=543)*	Non-OST/ DU (N=199)*	OST (N=96)*		
Male, % (n)	66.5 (361)	78.4 (156)	86.5 (83)	<0.001	n.s.
Age (years, mean $\pm$ SD)	51.9 (12.1)	47.8 (9.79)	44.4 (8.2)	<0.001	0.003
Caucasian, % (n)	96.9 (526)	98.5 (196)	99.0 (95)	n.s.	n.s.
HCV genotype, % (n)					
GT1	76.1 (413)	65.3 (130)	57.3 (855)	<0.001	n.s.
GT1a, % (n/N)	34.3 (186)	48.2 (96)	42.7 (41)	-	-
GT1b, % (n/N)	38.5 (209)	15.6 (31)	11.5 (11)	-	-
GT1 other subtypes	3.3 (18)	1.4 (3)	3.1 (3)	-	-
GT 2	6.4 (35)	4.5 (9)	7.3 (7)	n.s.	n.s.
GT 3	10.1 (55)	27.1 (54)	29.2 (28)	<0.001	n.s.
GT 4	7.4 (40)	3.0 (6)	6.3 (6)	n.s.	n.s.
GT 5 or 6	-	-	-	-	-
HCV RNA (IU/ml, mean $\pm$ SD)	2,904,596 (5,155,329)	3,604,412 (6,163,120)	4,820,365 (13,360,832)	0.015	n.s.
Treatment-experienced, % (n)	44.8 (243)	42.2 (84)	31.3 (30)	0.014	n.s.
IFN experienced, % (n/N)	96.3 (234/243)	96.4 (81/84)	100.0 (30/30)	n.s.	n.s.
FibroScan ≥ 12.5 kPa (F4), % (n/N)	20.3 (55/271)	20.9 (19/91)	21.1 (8/38)	n.s.	n.s.
Cirrhotic patients, % (n)	19.9 (108)	22.6 (45)	17.7 (17)	n.s.	n.s.
Platelets ($\times 10^9/l$, median, Q1–Q3)	203.0 (152.0–254.0)	186.0 (141.0–230.5)	185.0 (1142.0–222.0)	n.s.	n.s.
Platelets $< 90 \times 10^9/l$, % (n/N)	6.4 (33/517)	9.8 (19/193)	10.8 (10/93)	n.s.	n.s.
g-GT (IU/l, median, Q1–Q3)	72.0 (39.0–143.0)	85.0 (50.0–187.0)	104.5 (51.0–189.0)	0.026	n.s.
ALT (IU/l, median, Q1–Q3)	68.0 (45.0–122.0)	81.0 (53.0–123.5)	66.8 (42.0–112.5)	n.s.	n.s.
Comorbidities, % (n)	73.8 (401)	71.9 (143)	100.0 (96)	<0.001	<0.001
Cardiovascular disease, % (n)	26.7 (145)	16.6 (33)	14.6 (14)	0.010	n.s.
Diabetes mellitus, % (n)	8.3 (45)	5.5 (11)	2.1 (2)	0.032	n.s.
Psychiatric disorders, % (n)	14.5 (79)	15.6 (31)	21.9 (21)	n.s.	n.s.
Depression, % (n/N)	91.1 (72/79)	90.3 (28/31)	90.5 (19/21)	n.s.	n.s.
HCV/HIV co-infection, % (n)	16.8 (91)	11.6 (23)	8.3 (8)	0.033	n.s.

*if not otherwise indicated (specific lab data were not available for all patients)

Abbreviations: OST, opioid substitution therapy; non-OST, patients without OST; DU, former/current drug use and/or HCV transmission via drug abuse; NDU, no former/current drug use/other mode of HCV transmission; GT, HCV genotype; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IFN, interferon alpha; IU, international units; ml=millilitre; l=litre; p¹, p-value non-OST/NDU vs. OST; p², p-value non-OST/DU vs. OST; n.s., not significant, p>0.05

Table S2. Baseline characteristics of patients with alcohol consumption (>30/40 g/d)

Patient characteristics				p ¹	p ²
	Non-OST/ NDU (N=88)*	Non-OST/ DU (N=57)*	OST (N=32)*		
Male, % (n)	78.4 (69)	82.5 (47)	84.4 (27)	n.s.	n.s.
Age (years, mean ± SD)	51.0 (11.8)	48.3 (8.6)	47.7 (7.5)	n.s.	n.s.
Caucasian, % (n)	95.5 (84)	98.2 (56)	96.9 (31)	n.s.	n.s.
HCV genotype, % (n)					
GT1	64.8 (57)	57.9 (33)	71.9 (23)	n.s.	n.s.
GT1a	27.3 (24)	45.6 (26)	56.3 (18)	-	-
GT1b	34.1 (30)	12.3 (7)	15.6 (5)	-	-
GT1 other subtypes	3.0 (3)	-	-	-	-
GT 2	9.1 (8)	5.3 (3)	3.1 (1)	n.s.	n.s.
GT 3	15.9 (14)	33.3 (19)	21.9 (7)	<0.001	n.s.
GT 4	10.2 (9)	3.5 (2)	3.1 (1)	n.s.	n.s.
GT 5 or 6	-	-	-	-	-
HCV RNA (IU/ml, mean ± SD)	3,638,862 (8,890,601)	2,567,116 (3,116,803)	7,780,806 (16,028,518)	n.s.	0.019
Treatment-experienced, % (n)	33.0 (29)	35.1 (20)	31.3 (10)	n.s.	n.s.
IFN experienced, % (n/N)	100.0 (29/29)	90.0 (18/20)	100.0 (10/10)	n.s.	n.s.
FibroScan ≥12.5 kPa (F4), % (n/N)	27.0 (10/37)	39.5 (15/38)	53.3 (8/15)	n.s.	n.s.
Cirrhotic patients, % (n)	21.6 (19)	42.1 (24)	31.3 (10)	n.s.	n.s.
Platelets (×10 ⁹ /l, median, Q1–Q3)	189.0 (136.0–237.0)	194.5 (142.0–245.0)	183.0 (132.0–227.0)	0.023	n.s.
Platelets <90×10 ⁹ /l, % (n/N)	8.3 (6/72)	17.6 (9/51)	12.5 (4/28)	n.s.	n.s.
g-GT (IU/l, median, Q1–Q3)	133.0 (73.0–234.0)	136.8 (67.8–229.8)	232.0 (70.0–411.5)	0.044	n.s.
ALT (IU/l, median, Q1–Q3)	90.5 (53.0–154.0)	93.6 (59.5–143.5)	85.3 (34.5–140.0)	n.s.	n.s.
Comorbidities, % (n)	69.3 (61)	71.9 (143)	100.0 (32)	<0.001	<0.001
Cardiovascular disease, % (n)	18.2 (16)	17.5 (10)	9.4 (3)	n.s.	n.s.
Diabetes mellitus, % (n)	6.8 (6)	3.5 (2)	2.1 (2)	n.s.	n.s.
Psychiatric disorders, % (n)	13.6 (12)	17.5 (10)	25.0 (8)	n.s.	n.s.
Depression, % (n/N)	100.0 (12/12)	90.0 (9/10)	87.5 (7/8)	n.s.	n.s.
HCV/HIV co-infection, % (n)	19.3 (17)	5.3 (3)	3.1 (1)	0.040	n.s.

*if not otherwise indicated (specific lab data were not available for all patients)

Abbreviations: OST, opioid substitution therapy; non-OST, patients without OST; DU, former/current drug use and/or HCV transmission via drug abuse; NDU, no former/current drug use/other mode of HCV transmission; GT, HCV genotype; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IFN, interferon alpha; IU, international units; ml=millilitre; l=litre; p¹, p-value non-OST/NDU vs. OST; p², p-value non-OST/DU vs. OST; n.s., not significant, p>0.05

Table S3. Baseline characteristics of patients with no alcohol consumption

Patient characteristics				p ¹	p ²
	Non-OST/ NDU (N=4,790)*	Non-OST/ DU (N=1,206)*	OST (N=586)*		
Male, % (n)	50.6 (2,424)	72.1 (869)	77.8 (456)	<0.001	0.010
Age (years, mean ± SD)	55.9 (12.6)	48.4 (9.9)	45.7 (9.1)	<0.001	<0.001
Caucasian, % (n)	95.7 (4,584)	97.9 (1,181)	97.6 (572)	n.s.	n.s.
HCV genotype, % (n)					
GT1	82.9 (3,972)	70.6 (852)	66.6 (390)	<0.001	n.s.
GT1a	25.6 (1,226)	50.7 (612)	51.5 (302)	-	-
GT1b	53.0 (2,538)	16.6 (200)	12.1 (71)	-	-
GT1 other subtypes	4.3 (208)	3.3 (40)	2.9 (17)	-	-
GT 2	3.2 (152)	3.6 (44)	4.3 (25)	n.s.	n.s.
GT 3	8.4 (401)	21.2 (256)	25.6 (150)	<0.001	n.s.
GT 4	5.3 (252)	4.5 (54)	3.6 (21)	n.s.	n.s.
GT 5 or 6	0.3 (13)	-	-	-	-
HCV RNA (IU/ml, mean ± SD)	3,236,740 (21,332,839)	3,213,987 (9,260,124)	2,692,996 (4,782,665)	n.s.	n.s.
Treatment-experienced, % (n)	52.0 (2,493)	43.0 (518)	31.2 (183)	<0.001	<0.001
IFN experienced, % (n/N)	96.1 (2,396/2,493)	95.8 (496/518)	97.8 (179/183)	n.s.	n.s.
FibroScan ≥12.5 kPa (F4), % (n/N)	31.3 (498/1,593)	30.7 (123/401)	42.5 (82/193)	0.002	0.006
Cirrhotic patients, % (n)	29.7 (1,421)	27.4 (331)	29.7 (174)	n.s.	n.s.
Platelets (×10 ⁹ /l, median, Q1–Q3)	189.0 (136.0–237.0)	194.5 (142.0–245.0)	183.0 (132.0–227.0)	0.023	0.001
Platelets <90×10 ⁹ /l, % (n/N)	10.6 (472/4,473)	8.1 (92/1,132)	11.2 (64/569)	n.s.	0.040
g-GT (IU/l, median, Q1–Q3)	65.0 (35.0–120.0)	67.0 (37.0–124.0)	68.0 (37.0–133.0)	n.s.	n.s.
ALT (IU/l, median, Q1–Q3)	65.0 (43.0–104.0)	68.0 (43.0–111.0)	58.0 (33.3–95.0)	0.003	<0.001
Comorbidities, % (n)	72.5 (3,473)	75.0 (905)	100.0 (586)	<0.001	<0.001
Cardiovascular disease, % (n)	30.9 (1,480)	14.5 (175)	12.3 (72)	<0.001	n.s.
Diabetes mellitus, % (n)	11.8 (566)	7.0 (85)	4.3 (25)	<0.001	0.021
Psychiatric disorders, % (n)	13.2 (631)	21.6 (260)	25.1 (147)	<0.001	n.s.
Depression, % (n/N)	90.2 (569/631)	78.8 (205/260)	87.1 (128/147)	<0.001	0.017
HCV/HIV co-infection, % (n)	6.1 (291)	9.2 (111)	11.9 (70)	0.003	n.s.

*if not otherwise indicated (specific lab data were not available for all patients)

Abbreviations: OST, opioid substitution therapy; non-OST, patients without OST; DU, former/current drug use and/or HCV transmission via drug abuse; NDU, no former/current drug use/other mode of HCV transmission; GT, HCV genotype; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IFN, interferon alpha; IU, international units; ml=millilitre; l=litre; p¹, p-value non-OST/NDU vs. OST; p², p-value non-OST/DU vs. OST; n.s., not significant, p>0.05

Table S4. Baseline characteristics of patients with no cannabis consumption

Patient characteristics				p ¹	p ²
	Non-OST/ NDU (N=5,382)*	Non-OST/ DU (N=1,333)*	OST (N=586)*		
Male, % (n)	52.5 (2,823)	73.4 (979)	77.3 (453)	<0.001	n.s.
Age (years, mean ± SD)	55.5 (12.6)	48.3 (9.8)	45.2 (9.1)	<0.001	<0.001
Caucasian, % (n)	95.8 (5,157)	97.9 (1,305)	97.6 (572)	0.035	n.s.
HCV genotype, % (n)					
GT1	82.1 (4,416)	69.5 (927)	65.2 (382)	<0.001	n.s.
GT1a	26.2 (1,410)	49.7 (662)	51.0 (299)	-	-
GT1b	51.6 (2,780)	16.7 (223)	11.6 (68)	-	-
GT1 other subtypes	4.2 (226)	3.2 (42)	2.6 (15)	-	-
GT 2	3.6 (193)	3.7 (49)	4.4 (26)	n.s.	n.s.
GT 3	8.6 (463)	22.3 (297)	26.8 (157)	<0.001	0.036
GT 4	5.5 (297)	4.5 (60)	3.6 (21)	n.s.	n.s.
GT 5 or 6	0.2 (13)	-	-	-	-
HCV RNA (IU/ml, mean ± SD)	3,196,930 (20,197,911)	3,266,232 (9,044,354)	3,188,310 (6,919,652)	n.s.	n.s.
Treatment-experienced, % (n)	51.1 (2,752)	42.5 (566)	31.2 (1,839)	<0.001	<0.001
IFN experienced, % (n/N)	96.1 (2,646/2,752)	95.4 (540/566)	98.4 (180/183)	n.s.	n.s.
FibroScan ≥12.5 kPa (F4), % (n/N)	29.8 (561/1,881)	29.6 (142/480)	43.9 (87/198)	<0.001	<0.001
Cirrhotic patients, % (n)	28.6 (1,539/5,382)	26.9 (359/1,333)	29.5 (32/139)	n.s.	n.s.
Platelets (×10 ⁹ /l, median, Q1–Q3)	191.0 (138.0–239.0)	193.0 (142.0–240.0)	183.0 (132.5–224.0)	0.007	0.011
Platelets <90×10 ⁹ /l, % (n/N)	10.0 (504/5,025)	8.8 (110/1,257)	11.9 (68/572)	n.s.	0.041
g-GT (IU/l, median, Q1–Q3)	66.0 (36.0–123.0)	72.0 (39.0–134.0)	71.4 (41.0–144.0)	n.s.	n.s.
ALT (IU/l, median, Q1–Q3)	66.0 (43.0–107.7)	71.0 (45.0–114.0)	60.0 (37.0–102.0)	0.048	0.001
Comorbidities, % (n)	72.5 (3,903)	73.5 (980)	100.0 (586)	<0.001	<0.001
Cardiovascular disease, % (n)	30.5 (1,639)	15.2 (203)	13.1 (77)	<0.001	n.s.
Diabetes mellitus, % (n)	11.5 (618)	6.8 (91)	4.3 (25)	<0.001	0.029
Psychiatric disorders, % (n)	13.2 (710)	19.9 (265)	23.0 (135)	<0.001	n.s.
Depression, % (n/N)	90.6 (643/710)	79.2 (210/265)	85.9 (116/135)	<0.001	0.035
HCV/HIV co-infection, % (n)	7.1 (380)	9.1 (121)	10.1 (59)	0.012	n.s.

*if not otherwise indicated (specific lab data were not available for all patients)

Abbreviations: OST, opioid substitution therapy; non-OST, patients without OST; DU, former/current drug use and/or HCV transmission via drug abuse; NDU, no former/current drug use/other mode of HCV transmission; GT, HCV genotype; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IFN, interferon alpha; IU, international units; ml=millilitre; l=litre; p¹, p-value non-OST/NDU vs. OST; p², p-value non-OST/DU vs. OST; n.s., not significant, p>0.05